

=====

Exhibit 10.13.6

CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS  
DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED  
WITH THE COMMISSION \* \* \*

CONFIDENTIAL TREATMENT

AMENDMENT TO DEVELOPMENT AGREEMENT

Amendment dated November 30, 2004, to that certain Development Agreement dated March 7, 2003, between INyX Pharma, Ltd. and Stiefel Laboratories, Inc.

Exhibit B to the Development Agreement is hereby amended to add the product specified below.

In all other respects the Development Agreement shall remain in effect in its original form.

Dated the date first-above written.

INyX PHARMA LIMITED.

By: /s/ Steven J. Handley

-----  
Steven J. Handley, President

STIEFEL LABORATORIES, INC.

By: /s/ William A. Carr

-----  
William A. Carr, Vice President

CONFIDENTIAL TREATMENT

ADDENDUM TO  
EXHIBIT B

SCHEDULE OF DEVELOPMENT ACTIVITIES

IV. Task Name: \*\*\*

Start Date: \*\*\*

Finish Date: \*\*\*

1. Project definition and scope.
2. Acquisition, Testing, and Evaluation of drugs, excipients, and components as agreed by both parties.
3. Formulation and manufacturing process assessments to facilitate production of the product by Inyx.
4. Assessment and assistance, as necessary, in the development of mutually acceptable test methods required to secure health registrations.
5. Development and Exhibit batch preparation.
6. Development and preparation of necessary clinical supplies.
7. Assistance, as necessary, with mutually agreed testing activities to support health registrations.
8. Support in preparation and review of CMC documentation necessary to secure health registrations.

TOTAL DEVELOPMENT COST \*\*\*.

-----  
\*\*\* Confidential material redacted and filed separately with the Commission.